HNHA

HNHA is a cell-permeable inhibitor of histone deacetylase (HDAC) activity (IC50 = 100 nM). In human fibrosarcoma HT1080 cells, it induces histone hyperacetylation and p21 transcription with concomitant inhibition of cell cycle progression (IC50 ~7.5 µM). HNHA is at least as effective as SAHA in inhibiting tumor growth in a murine xenograph model in vivo. HNHA also blocks the growth of human umbilical vein endothelial cells (HUVECs) and prevents tube formation and migration of HUVECs in response to vascular endothelial growth factor (VEGF). It also blocks retinal neovascularization and choroidal angiogenesis in mice.Formal Name: N-hydroxy-7-(2-naphthalenylthio)-heptanamide. CAS Number: 926908-04-5. Synonyms: Histone Deacetylase Inhibitor VI. Molecular Formula: C17H21NO2S. Formula Weight: 303.4. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml, Ethanol: 20 mg/ml. lambdamax: 218, 254, 284 nm. SMILES: c1ccc2c(c1)cc(cc2)SCCCCCCC(NO)=O. InChi Code: InChI=1S/C17H21NO2S/c19-17(18-20)9-3-1-2-6-12-21-16-11-10-14-7-4-5-8-15(14)13-16/h4-5,7-8,10-11,13,20H,1-3,6,9,12H2,(H,18,19). InChi Key: KPNNXHVGOKRBEF-UHFFFAOYSA-N.